Pathological characteristics of patients with diabetes mellitus tipe 2, in Spanish primary care;Perfil de los pacientes con diabetes mellitus tipo 2, en la Atención Primaria española

Revista Clinica Espanola

Volumn 204, Issue 1, 2004, Pages 18-24

  Benito Lopez P ^a   Garcia Mayor R ^b   Puig Domingo, M ^c   Mesa Manteca, J ^d   Pallardo Sanchez L F ^e   Faure Nogueras, E ^f   Ravella Mateu, R ^g   Artes Ferragud M ^h   Salvador Lopez J ^h  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b HOSPITAL XERAL CÍES   (Spain)

^c HOSPITAL DE MATARÓ   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^g Depto Medico Sanofi Synthelabo   (Spain)

^h PharmaConsult Services   (Spain)

Author keywords

Cardiovascular risk factors; Diabetes mellitus type 2; Diabetes treatment; Primary care

Indexed keywords

ANTIDIABETIC AGENT; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ANTHROPOMETRY; ARTICLE; BODY WEIGHT; CHI SQUARE TEST; CORRELATION COEFFICIENT; CORRESPONDENCE ANALYSIS; DETERIORATION; DIABETES CONTROL; DISEASE COURSE; DISEASE DURATION; DRINKING BEHAVIOR; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OPEN STUDY; PATIENT CODING; PRIMARY MEDICAL CARE; RISK FACTOR; SMOKING; SPAIN; STUDENT T TEST; SUBSTANCE ABUSE; SYMPTOMATOLOGY;

EID: 1442301064     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1157/13056787     Document Type: Article

References (31)

1. Prevention of diabetes mellitus: report of a WHO study group. Geneva, World Health Organization, 1994. (WHO technical report series no. 844).
2. Andersson DKG, Svärdsudd K, Tibblin G. Prevalence and incidence of diabetes in a Swedish community 1972-1987. Diabetic Med 1991;8:428-34.
3. Papazoglou N, Manes C, Chatzimitrofannous P. Epidemiology of diabetes mellitus in the elderly in northen Greece: a population study. Diabetic Med 1995;12:397-400.
4. Mata M, Cos X, Bobé I, Pujol E, Royo C, Centelles R, et al. Diabetes mellitus tipo 2: incidencia y diagnóstico en un centro de atención primaria. Aten Primaria 2000;25:469-78.
5. Tamayo B, Faure E, Roche MJ, Rubio E, Sánchez Oriz E, Salvador JA. Prevalence of diabetes and impaired glucose tolerance in Aragón, Spain. Diabetes Care 1997;20:534-6.
6. Bayo J, Latorre PM, García F, Vázquez JA. Factores, de riesgo asociados a la prevalencia de diabetes mellitus no insulinodependiente en Lejona (Vizcaya). Med Clin 1996;107:572-7.
7. Kaplan NM. The deadly quartet. Upper body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Int Med 1989;149:1514-20.
8. De Fronzo R, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dislipemia and atherosclerotic cardiovacular disease. Diabetes Care 1991;14:173-94.
9. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Horlman RR, for the United Kingdom Prospective Diabetes Study Group. Risk factors for coronary artery disease in noninsulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ 1998;316:823-8.
10. Balletshofer BM, Rittig K, Enderle MD, Volk A, Maerker E, Jacob S, et al. Endothelial dysfunction is detectable in young normotensive first degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000;101:1780-4.
11. Jager A, Hinsberg V, Kostense P, Emeis J, Nijpels G, Dekker J, et al. Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes. The Hoorn study. Diabetes 2000;49:485-91.
12. Hedblad B, Nilsson P, Janzon L, Berglund G. Relation between insulin resistance and carotid intima media thickness and stenosis in non diabetic subjects. Results from a cross sectional study in Malmö, Sweden. Diabetic Med 2000;17:299-307.
13. Haffner SM, Agostino RD Jr, Saad MF, O'Leary DH, Savage PJ, Rewers M, et al. Carotid artery atherosclerosis in type-2 diabetic and nondiabetic subjects with and without symptomatic coronary artery disease (The Insulin Resistance Atherosclerosis Study). Am J Cardiol 2000;85:1395-400.
14. Miettinen H, Lehto S, Salomaa V, Mahonen M, Niemela M, Haffner S, et al. Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care 1998;21:69-75.
15. Laakso M, Letho S. Epidemiology of macrovascular disease in diabetes. Diabetes Rev 1997;5:294-315.
16. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonilureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
17. Stratton I, Adler A, Neil A, Matthews D, Manley S, Cull C, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405-12.
18. Gaede P, Vedel P, Parving H, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999;353:617-22.
19. Puig Domingo M. Control of postprandrial state abnormalities: meeting the challenge of type 2 diabetes? Eur J Clin Inv 2000;(Suppl 2):19-24.
20. European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes mellitus. Diabetic Med 1999;16:716-30.
21. Benito P, Faure E, García Mayor R, Mesa J, Pallardo LF, Puig D, et al. Evaluación de los criterios del European Diabetes Policy Group 1999 en la cohorte del estudio Midia. Resultados finales. Endocrinol Nutrición 2001;48:27.
22. Costa B, Utgés P, Monclús F, Gomis T, Ciurana MR, Julve P y el grup, per a l'estudi de la diabetis a Tarragona. Consumo de medicación en la diabetes mellitus (1). Estimación del perfil terapéutico y la prevalencia en las comarcas de Tarragona (548.900 habitantes). Med Clin 1992;99:294-9.
23. Fernández Herraez E, Ferré Larrosa F, Jiménez Alfonso L, Arnaldos J. Valoración de los factores relacionados con el control de la glucemia en la diabetes mellitus tipo 2. Aten Primaria 1999;24:39-43.
24. Clemente ML, Alonso JA, Córdoba R, Cortada J, Grandes G, Nebot M, et al. Descripción de las guías disponibles en España para el abordaje del tabaquismo en Atención Primaria. Aten Primaria 1999;24:101-8.
25. Aranceta J. Epidemiología de la obesidad en los países desarrollados. Nutrición Hospitalaria 1998;1:12-22.
26. Narejos S, Espinas J, Rodríguez A, Salla RM, Puente A, Cantero M, et al. Análisis de costes y grado de control de la hipercolesterolemia en los pacientes diabéticos tipo 2 según distintos grupos y sociedades científicas. Aten Primaria 2000;26;145-50.
27. Cuesta T, Escortell E, Fernández MI, López Bilbao C, Medina C, Torres C, et al. Calidad del tratamiento farmacológico en pacientes con hiperlipemia de 4 áreas de salud. Aten Primaria 2000;26:368-73.
28. Sáez E, Millán A, López de Castro F, Carrasco J, Arribas A, Albarca MJ. Grado de control y atención a los pacientes con hipertensión en el área de salud de Toledo. Aten Primaria 1999;24:559-62.
29. Turner R, Cull C, Frighi V, Holman R, for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-12.
30. Goday A, Mata M. Criterios y pautas de terapia combinada en la diabetes tipo 2. Documento de consenso de la Sociedad Española de Diabetes y de la Sociedad Española de Medicina Familiar y Comunitaria. Endocrinol Nutrición 2001;48:44-65.
31. Howard B, Howard W. Dyslipemia in non insulin dependent diabetes mellitus. Endocrinol Rew 1994;15:263-74.